Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Yin, M. O'Brien, R. Hills, Sarah Daly, K. Wheatley, A. Burnett (2007)Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
Blood, 120 14
E. Estey, H. Döhner (2006)Acute myeloid leukaemia
The Lancet, 368
E. Natelson (2007)Benzene‐induced acute myeloid leukemia: A clinician's perspective
American Journal of Hematology, 82
F. Buccisano, L. Maurillo, V. Gattei, G. Poeta, M. Principe, Maria Cox, P. Panetta, M. Consalvo, Carla Mazzone, B. Neri, L. Ottaviani, D. Fraboni, A. Tamburini, F. Lo‐Coco, S. Amadori, A. Venditti (2006)The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia
K. Mrózek, G. Marcucci, D. Nicolet, K. Maharry, H. Becker, S. Whitman, K. Metzeler, S. Schwind, Yue-zhong Wu, J. Kohlschmidt, M. Pettenati, N. Heerema, A. Block, S. Patil, M. Baer, J. Kolitz, J. Moore, A. Carroll, R. Stone, R. Larson, C. Bloomfield (2012)Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 36
By Grimwade, H. Walker, F. Oliver, K. Wheatley, C. Harrison, G. Harrison, J. Rees, I. Hann, R. Stevens, A. Burnett, A. Goldstone (1998)The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
Blood, 92 7
E. Sievers, B. Lange, T. Alonzo, R. Gerbing, I. Bernstein, F. Smith, R. Arceci, W. Woods, M. Loken (2002)Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
M. Ratain, J. Rowley (1992)Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes.
Annals of oncology : official journal of the European Society for Medical Oncology, 3 2
W. Blum, R. Garzon, R. Klisovic, S. Schwind, A. Walker, S. Geyer, Shujun Liu, V. Havelange, H. Becker, L. Schaaf, J. Mickle, H. Devine, C. Kefauver, S. Devine, K. Chan, N. Heerema, C. Bloomfield, M. Grever, J. Byrd, M. Villalona-Calero, C. Croce, G. Marcucci (2010)Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
Proceedings of the National Academy of Sciences, 107
T. Kalina, J. Flores-Montero, V. Velden, M. Martín-Ayuso, S. Böttcher, M. Ritgen, J. Almeida, L. Lhermitte, V. Asnafi, Alexandre Mendonça, R. Tute, M. Cullen, L. Sędek, M. Vidriales, J. Perez, J. Marvelde, E. Mejstrikova, O. Hrusak, T. nacute, ski, J. Dongen, A. Órfão (2012)EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols
N. Hosen, Christopher Park, N. Tatsumi, Y. Oji, H. Sugiyama, M. Gramatzki, A. Krensky, I. Weissman (2007)CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia
Proceedings of the National Academy of Sciences, 104
U. Platzbecker, M. Wermke, J. Radke, U. Oelschlaegel, F. Seltmann, Alexander Kiani, Ina-Maria Klut, Holger Knoth, C. Röllig, J. Schetelig, B. Mohr, X. Graehlert, Gerhard Ehninger, Martin Bornhäuser, C. Thiede (2011)Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
J. Byrd, K. Mrózek, R. Dodge, A. Carroll, C. Edwards, D. Arthur, M. Pettenati, S. Patil, K. Rao, M. Watson, P. Koduru, J. Moore, R. Stone, R. Mayer, E. Feldman, F. Davey, C. Schiffer, R. Larson, C. Bloomfield (2002)Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
Blood, 100 13
U. Bacher, A. Badbaran, B. Fehse, T. Zabelina, A. Zander, N. Kröger (2009)Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.
Experimental hematology, 37 1
Dr. Nurul, Akhtar Hasan, Mohammad Mamun (1997)Leading article
Sonali Smith, M. Beau, D. Huo, T. Karrison, R. Sobecks, J. Anastasi, J. Vardiman, J. Rowley, R. Larson (2003)Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.
Blood, 102 1
W. Kern, D. Voskova, C. Schoch, W. Hiddemann, S. Schnittger, T. Haferlach (2004)Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.
Blood, 104 10
R. Majeti, M. Chao, Ash Alizadeh, W. Pang, S. Jaiswal, Kenneth Gibbs, N. Rooijen, I. Weissman (2009)CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
J. Rubnitz, H. Inaba, G. Dahl, Raul Ribeiro, W. Bowman, J. Taub, S. Pounds, B. Razzouk, N. Lacayo, Xueyuan Cao, S. Meshinchi, B. Degar, G. Airewele, S. Raimondi, M. Onciu, E. Coustan-Smith, J. Downing, W. Leung, C. Pui, D. Campana (2010)Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
The Lancet. Oncology, 11 6
A. Rhenen, N. Feller, A. Kelder, A. Westra, E. Rombouts, S. Zweegman, M. Pol, Q. Waisfisz, G. Ossenkoppele, G. Schuurhuis (2005)High Stem Cell Frequency in Acute Myeloid Leukemia at Diagnosis Predicts High Minimal Residual Disease and Poor Survival
Clinical Cancer Research, 11
W. Leung, C. Pui, E. Coustan-Smith, Jie Yang, D. Pei, K. Gan, A. Srinivasan, C. Hartford, B. Triplett, M. Dallas, Asha Pillai, D. Shook, J. Rubnitz, J. Sandlund, S. Jeha, H. Inaba, R. Ribeiro, R. Handgretinger, J. Laver, D. Campana (2012)Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.
Blood, 120 2
Jay Patel, M. Gönen, M. Figueroa, H. Fernandez, Zhuoxin Sun, J. Racevskis, P. Vlierberghe, I. Dolgalev, S. Thomas, Olga Aminova, K. Huberman, Janice Cheng, A. Viale, N. Socci, A. Heguy, A. Cherry, G. Vance, R. Higgins, R. Ketterling, R. Gallagher, M. Litzow, M. Brink, H. Lazarus, J. Rowe, S. Luger, A. Ferrando, E. Paietta, M. Tallman, A. Melnick, O. Abdel-Wahab, R. Levine (2012)Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
The New England journal of medicine, 366 12
B. Cheson, John Bennett, K. Kopecky, T. Büchner, Cheryl Willman, E. Estey, Charles Schiffer, H. Doehner, Martin Tallman, T. Lister, F. Lo‐Coco, R. Willemze, A. Biondi, W. Hiddemann, Richard Larson, B. Löwenberg, Miguel Sanz, David Head, R. Ohno, Clara Bloomfield (2003)Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 24
A. Rhenen, G. Dongen, A. Kelder, E. Rombouts, N. Feller, B. Moshaver, M. Walsum, S. Zweegman, G. Ossenkoppele, Gerrit Schuurhuis (2005)The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells.
Blood, 110 7
F. Appelbaum, K. Kopecky, M. Tallman, M. Slovak, H. Gundacker, Haesook Kim, G. Dewald, H. Kantarjian, S. Pierce, E. Estey (2006)The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations
British Journal of Haematology, 135
Jonathan Gerber, B. Smith, Brownhilda Ngwang, Hao Zhang, M. Vala, L. Morsberger, Steven Galkin, M. Collector, B. Perkins, M. Levis, Constance Griffin, S. Sharkis, M. Borowitz, J. Karp, Richard Jones (2012)A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia.
Blood, 119 15
T. Prebet, N. Boissel, S. Reutenauer, X. Thomas, J. Delaunay, J. Cahn, A. Pigneux, B. Quesnel, F. Witz, S. Thépot, V. Ugo, C. Terré, C. Récher, E. Tavernier, M. Hunault, B. Esterni, S. Castaigne, F. Guilhot, H. Dombret, N. Vey (2009)Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 28
J. Rowe (2011)Evaluation of prognostic factors in AML. Preface.
Best practice & research. Clinical haematology, 24 4
Max Jan, T. Snyder, M. Corces-Zimmerman, P. Vyas, I. Weissman, S. Quake, R. Majeti (2012)Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia
Science Translational Medicine, 4
D. Campana, E. Coustan-Smith, G. Janossy (1990)The immunologic detection of minimal residual disease in acute leukemia.
Blood, 76 1
J. Miguel, M. Vidriales, C. López-Berges, J. Díaz-Mediavilla, N. Gutiérrez, C. Cañizo, F. Ramos, M. Calmuntia, J. Pérez, Marcos González, A. Órfão (2001)Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification.
Blood, 98 6
F. Marchesi, O. Annibali, E. Cerchiara, M. Tirindelli, G. Avvisati (2011)Cytogenetic abnormalities in adult non-promyelocytic acute myeloid leukemia: a concise review.
Critical reviews in oncology/hematology, 80 3
W Blum, R Garzon, RB Klisovic, S Schwind, A Walker, S Geyer, S Liu, V Havelange, H Becker, L Schaaf, J Mickle, H Devine, C Kefauver, SM Devine, KK Chan, NA Heerema, CD Bloomfield, MR Grever, JC Byrd, M Villalona-Calero, CM Croce, G Marcucci (2010)Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
Proc Natl Acad Sci USA, 107
F. Buccisano, L. Maurillo, A. Spagnoli, M. Principe, E. Ceresoli, F. Coco, W. Arcese, S. Amadori, A. Venditti (2009)Monitoring of minimal residual disease in acute myeloid leukemia
Current Opinion in Oncology, 21
G. Roboz (2012)Current treatment of acute myeloid leukemia
Current Opinion in Oncology, 24
N Hosen, CY Park, N Tatsumi, Y Oji, H Sugiyama, M Gramatzki, AM Krensky, IL Weissman (2007)CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia
Proc Natl Acad Sci USA, 104
A. Al-Mawali, D. Gillis, I. Lewis (2009)The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
American journal of clinical pathology, 131 1
A. Rhenen, B. Moshaver, A. Kelder, N. Feller, A. Nieuwint, S. Zweegman, G. Ossenkoppele, G. Schuurhuis (2007)Aberrant marker expression patterns on the CD34+CD38− stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission
Uta Oelschlgel, Ralf Nowak, A. Schaub, Christine Kppel, Regina Herbst, Brigitte Mohr, Christine Lffler, Ursula Range, Heinrich Gnther, Michael Amann, Elke Siegert, Elisabeth Wendt, Renate Huhn, Elisabeth Brutigam, Gerhard Ehninger (2000)Shift of aberrant antigen expression at relapse or at treatment failure in acute leukemia.
Cytometry, 42 4
P. Chauvel (1992)Osteosarcomas and adult soft tissue sarcomas: is there a place for high LET radiation therapy?
Annals of oncology : official journal of the European Society for Medical Oncology, 3 Suppl 2
G. Gianfaldoni, F. Mannelli, M. Baccini, E. Antonioli, F. Leoni, A. Bosi (2006)Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study
British Journal of Haematology, 134
C. Jordan, D. Upchurch, S. Szilvassy, M. Guzman, D. Howard, AL Pettigrew, T. Meyerrose, R. Rossi, B. Grimes, D. Rizzieri, S. Luger, G. Phillips (2000)The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells
T. Köhnke, D. Sauter, K. Ringel, J. Braess, W. Hiddemann, K. Spiekermann, M. Subklewe (2011)A Combined Score of Minimal Residual Disease (MRD) Assessment by Flow Cytometry, Cytogenetic and Molecular Markers As Well As Age Predicts Outcome and Can Potentially Guide MRD-Based Therapy in Acute Myeloid Leukemia
F. Thol, Britta Kölking, F. Damm, K. Reinhardt, J. Klusmann, D. Reinhardt, N. Neuhoff, M. Brugman, B. Schlegelberger, S. Suerbaum, J. Krauter, A. Ganser, M. Heuser (2012)Next‐generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3‐ITD or NPM1 mutations
A. Venditti, F. Buccisano, G. Poeta, L. Maurillo, A. Tamburini, C. Cox, Alessandra Battaglia, G. Catalano, B. Moro, L. Cudillo, M. Postorino, M. Masi, S. Amadori (2000)Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia.
Blood, 96 12
D. Bonnet, J. Dick (1997)Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
Nature Medicine, 3
Christopher Reading, Eli Estey, Yang Huh, D. Claxton, G. Sánchez, L. Terstappen, M. O'Brien, S. Baron, A. Deisseroth (1993)Expression of unusual immunophenotype combinations in acute myelogenous leukemia.
Blood, 81 11
G. Roboz, M. Guzman (2009)Acute myeloid leukemia stem cells: seek and destroy
Expert Review of Hematology, 2
A. Corbacioglu, C. Scholl, R. Schlenk, Karina Eiwen, Juan Du, L. Bullinger, S. Fröhling, P. Reimer, M. Rummel, H. Derigs, D. Nachbaur, J. Krauter, A. Ganser, H. Döhner, K. Döhner (2010)Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 23
H. Inaba, E. Coustan-Smith, Xueyuan Cao, Stanley Pounds, S. Shurtleff, Kathleen Wang, S. Raimondi, M. Onciu, J. Jacobsen, Raul Ribeiro, Gary Dahl, W. Bowman, Jeffrey Taub, B. Degar, W. Leung, J. Downing, C. Pui, J. Rubnitz, D. Campana (2012)Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 29
Zhantao Yang, R. Doty, M. Nguyen, Ann Smith, J. Abkowitz (2007)Evidence That Heme Export Via the Feline Leukemia Virus, Subgroup, C Receptor (FLVCR) Is Carrier Dependent and Its Physiological Implications.
T. Burmeister, R. Marschalek, B. Schneider, C. Meyer, N. Gökbuget, S. Schwartz, D. Hoelzer, E. Thiel (2006)Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations
In the past year, there has been increasing attention towards understanding the clinical relevance of minimal residual disease (MRD) assessment. The monitoring of MRD levels at various stages of therapy has considerable potential to impact the guidance of treatment for AML patients and improve outcomes. Thus, efforts have increased to address important concerns regarding MRD measurements. These concerns include: (1) what should be monitored; (2) what methodologies should be used; (3) whether such methodologies are standardized across laboratories; (4) how prognostic levels are defined; (5) when MRD should be monitored; and (6) what treatment options are available for MRD positive patients. In this review, we will discuss the methodologies available for MRD and the studies available to date aiming to address the concerns around the use of MRD measurements for AML patients
Current Hematologic Malignancy Reports – Springer Journals
Published: Apr 6, 2013
Access the full text.
Sign up today, get DeepDyve free for 14 days.